换一批Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
第一作者：
Nancy M,Albert
第一单位：
Research and Innovation, Cleveland Clinic Health System, USA; George M and Linda H Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue J3-4, Cleveland, OH 44195, USA. Electronic address: albertn@ccf.org.
作者：
关键词
AFAtrial fibrillationCHA(2)DS(2)-VAScCHADS(2)CICrClDabigatranGIHAS-BLEDICHINRMINovel oral anticoagulantsRRRivaroxabanTTRWarfarinatrial fibrillationcardiac failure, hypertension, age, diabetes, stroke (doubled)confidence intervalcongestive heart failure, hypertension, age ≥75 years (doubled), diabetes, previous stroke or transient ischemic attack (doubled), vascular disease, sex categorycreatinine clearancegastrointestinalhypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcoholinternational normalized ratiointracranial hemorrhagemyocardial infarctionrelative risktime in therapeutic range
医学主题词
投药, 口服(Administration, Oral);抗凝药(Anticoagulants);心房颤动(Atrial Fibrillation);苯咪唑类(Benzimidazoles);出血(Hemorrhage);人类(Humans);吗啉类(Morpholines);血小板聚集抑制剂(Platelet Aggregation Inhibitors);吡唑类(Pyrazoles);吡啶酮类(Pyridones);危险性评估(Risk Assessment);卒中(Stroke);噻吩类(Thiophenes);华法林(Warfarin);β丙氨酸(beta-Alanine)
DOI
10.1016/j.hrtlng.2013.10.014
PMID
24373340
发布时间
2018-12-02
- 浏览84
Heart & lung
48-59页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
